Charles River Laboratories International and Autolomous have launched a new Laboratory Execution System (LES), named Apollo Orchestrate, that will be rolled out at the CRO's Biologics Testing Solutions sites in North America and Europe.
Autolomous' autoloMATE technology will underpin the platform, connecting Charles River's laboratory systems, including Apollo and LabWare LIMS, supporting digital traceability from sample submission through execution to release.
The pair said the new system will support quality control (QC) testing within the GMP setting.
"Aligned with our modernisation strategy, it is crucial that we evolve quickly to enhance efficiencies and ensure medicines reach patients swiftly and safely," said Kerstin Dolph, Corporate Senior Vice President of Global Manufacturing, Charles River.
The launch of Apollo Orchestrate, built on Autolomous' autoloMATE platform, will increase efficiency while providing greater transparency and collaboration for our clients, both of which are key to our strategic goals.
The launch is the next step in Charles River's development of an integrated digital laboratory ecosystem, with the company hoping it will enable a more seamless workflow focused on delivering results to clients rapidly and accurately.
Apollo Orchestrate connects sample submission, laboratory execution and review into one digital workflow and shifts records from paper to digital, with a path to greater client visibility.
It improves efficiency by minimising manual processes, improving data accuracy, accelerating execution and review, as well as allowing technical and QA teams to spend less time on administrative review and more on scientific, quality and client-focused work.
Initial deployment within the GMP setting for QC testing will establish a standardised, scalable operating model for expansion across Biologics Testing Solutions sites following the initial go-live.
"Biological testing proves that a medicine is safe, effective and ready for patients, but data collection and management across fragmented, often manual and paper-based systems from R&D to commercial release create unnecessary delays for patients, opportunities for errors, audit risks and lost revenue," added Alexander Seyf, CEO of Autolomous.
We designed autoloMATE to enable life sciences companies to connect that data directly into an integrated, digitised workflow and increase speed, accuracy and cost-effectiveness.
